Skip to content

Glaxo to Supply U.S. With $1 Billion of Covid Antibody in Weeks

  • U.S. doses to be delivered to U.S. government by Dec. 17
  • Glaxo, partner Vir say sotrovimab appears effective on delta
The headquarter offices of Glaxosmithkline Plc in London.
Photographer: Luke MacGregor/Bloomberg

GlaxoSmithKline Plc and Vir Biotechnology Inc. will supply $1 billion worth of doses of their Covid-19 antibody treatment to the U.S. in the next month. 

The companies announced a contract on Wednesday that brings the number of doses ordered to 750,000 worldwide, they said in a statement. The medicine, sotrovimab, can prevent Covid patients from becoming severely ill.